Achieve Life Sciences Inc
NASDAQ:ACHV

Watchlist Manager
Achieve Life Sciences Inc Logo
Achieve Life Sciences Inc
NASDAQ:ACHV
Watchlist
Price: 3.69 USD -3.4%
Market Cap: 126.7m USD
Have any thoughts about
Achieve Life Sciences Inc?
Write Note

Achieve Life Sciences Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Achieve Life Sciences Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Achieve Life Sciences Inc
NASDAQ:ACHV
Net Income (Common)
-$32.9m
CAGR 3-Years
-2%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$126m
CAGR 3-Years
-74%
CAGR 5-Years
-46%
CAGR 10-Years
-35%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

Achieve Life Sciences Inc
Glance View

Market Cap
126.9m USD
Industry
Biotechnology

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 16 full-time employees. The firm is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. The firm is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties. The Company’s has two prescription oral treatments for smoking cessation are available in the United States: Chantix (varenicline) and Zyban (bupropion).

ACHV Intrinsic Value
5.1 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Achieve Life Sciences Inc's Net Income (Common)?
Net Income (Common)
-32.9m USD

Based on the financial report for Sep 30, 2024, Achieve Life Sciences Inc's Net Income (Common) amounts to -32.9m USD.

What is Achieve Life Sciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-2%

Over the last year, the Net Income (Common) growth was 7%. The average annual Net Income (Common) growth rates for Achieve Life Sciences Inc have been -2% over the past three years , -14% over the past five years , and -2% over the past ten years .

Back to Top